ENFUVIRTIDE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/12457443 | https://www.ncbi.nlm.nih.gov/pubmed/30836922 | https://www.ncbi.nlm.nih.gov/pubmed/30000878 | https://www.drugbank.ca/drugs/DB00109 | https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021481s032lbl.pdf

Enfuvirtide is a linear 36-amino acid synthetic peptide that inhibits the fusion of HIV-1 with CD4 cells. Enfuvirtide works by disrupting the HIV-1 molecular machinery at the final stage of fusion with the target cell, preventing uninfected cells from becoming infected. Enfuvirtide interferes with the entry of HIV-1 into cells by inhibiting fusion of viral and cellular membranes. Enfuvirtide binds to the first heptad-repeat (HR1) in the gp41 subunit of the viral envelope glycoprotein and prevents the conformational changes required for the fusion of viral and cellular membranes. Enfuvirtide is indicated for the treatment of HIV-1 infection, in combination therapy with other antiretrovirals, in patients where all other treatments have failed. Common adverse drug reactions associated with enfuvirtide therapy include: injection site reactions (pain, hardening of skin, erythema, nodules, cysts, itch; experienced by nearly all patients, particularly in the first week), peripheral neuropathy, insomnia, depression, cough, dyspnoea, anorexia, arthralgia, infections (including bacterial pneumonia) and/or eosinophilia.

Approval Year

Conditions

Condition	Modality	Targets	Highest Phase	Product
HIV-1 infection 150 Sources: https://www.drugs.com/pro/FUZEON.html	Primary		Approved 8360	FUZEON Approved Use FUZEON is an HIV-1 fusion inhibitor indicated for use in combination with other antiretroviral agents for the treatment of HIV-1 infection in treatment experienced patients with HIV-1 replication despite ongoing antiretroviral therapy. Launch Date 1.0475136E12

PubMed

Title	Date	PubMed
[T-20: a fusion inhibitor].	2002	12703471
HIV medicine after Barcelona conference: interview with Howard Grossman, M.D. Interview by John S. James.	2002 Sep 6	12765126
ConFuzeon reigns.	2003 Apr	12751446
Anti-HIV-1 activity of enfuvirtide (T-20) by inhibition of bystander cell death.	2003 Apr	12741628
The LLSGIV stretch of the N-terminal region of HIV-1 gp41 is critical for binding to a model peptide, T20.	2003 Apr	12736375
Drug cost. States concerned about Fuzeon.	2003 Apr 11	12728848
Stopping HIV fusion with enfuvirtide: the first step to extracellular HAART.	2003 Feb	12562683
David Reddy--taking HIV therapy to new frontiers. Interview by Pam Das.	2003 Feb	12560198
Human immunodeficiency virus type 1 attachment, coreceptor, and fusion inhibitors are active against both direct and trans infection of primary cells.	2003 Feb	12552019
Anti-HIV drug updates--three drugs on the near horizon.	2003 Jan	12647672
Projecting future drug expenditures--2003.	2003 Jan 15	12561658
Synthesis of maleimide-activated carbohydrates as chemoselective tags for site-specific glycosylation of peptides and proteins.	2003 Jan-Feb	12526713
First fusion inhibitor for advanced HIV.	2003 Jul	12877130
Large-scale manufacture of peptide therapeutics by chemical synthesis.	2003 Jul	12815383
[HIV infections: further options for combination therapy].	2003 Jul 11	12899165
FDA notifications. FDA approves Fuzeon, the first fusion inhibitor.	2003 Jun	12866478
Antiviral Research--16th Annual International Conference. Satellite symposium: clinical update on antiviral drugs. 27 April-1 May 2003, Savannah, GA, USA.	2003 Jun	12861974
Gateways to clinical trials.	2003 Jun	12851663
Uncommon mutations at residue positions critical for enfuvirtide (T-20) resistance in enfuvirtide-naive patients infected with subtype B and non-B HIV-1 strains.	2003 Jun 1	12794544
[First fusion inhibitor is available. No entry for HIV-1 viruses].	2003 Jun 19	12891854
Enfuvirtide (Fuzeon) for HIV Infection.	2003 Jun 23	12817195
Treatment with a new fusion inhibitor: patient issues with enfuvirtide (T-20). A review of the presentation at the satellite symposium "New hope: advancing care in HIV infection" at the 15th annual Association of Nurses in AIDS Care conference, November 2002.	2003 Mar	12765161
Clinical safety and efficacy of enfuvirtide (T-20), a new fusion inhibitor. A review of the presentation at the satellite symposium "New hope: advancing care in HIV infection" at the 15th annual Association of Nurses in AIDS Care conference, November 2002.	2003 Mar	12765160
New classes of HIV drugs on the horizon. A review of the presentation at the satellite symposium "New hope: advancing care in HIV infection" at the 15th annual Association of Nurses in AIDS Care conference, November 2002.	2003 Mar	12765159
Gateways to clinical trials. March 2003.	2003 Mar	12731460
FUZEON (enfuvirtide, T-20). Breaking barriers or breaking the bank?	2003 Mar	12728858
Fuzeon data review.	2003 Mar	12728857
Long path to approval. A look back at the road to Fuzeon.	2003 Mar	12728856
Entry inhibitors SCH-C, RANTES, and T-20 block HIV type 1 replication in multiple cell types.	2003 Mar	12689409
T-20: most expensive AIDS drug ever at $25,000 per year?	2003 Mar 14	12712938
A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy.	2003 Mar 28	12646792
Fusion inhibitor approved.	2003 May	12816619
Drug profile: enfuvirtide (Fuzeon, ENF, T-20).	2003 May	12809104
The optimal use of enfuvirtide.	2003 May	12809103
Enfuvirtide access, administration, and patient education.	2003 May	12809102
Enfuvirtide.	2003 May	12755128
FDA news. Price criticized for new anti-HIV drug.	2003 May	12751460
Enfuvirtide approved for defusing HIV.	2003 May	12726955
US FDA approves new class of HIV therapeutics.	2003 May	12721558
Enfuvirtide, a new drug for HIV infection.	2003 May 10	12747873
Primary resistance mutations to fusion inhibitors and polymorphisms in gp41 sequences of HIV-1 non-B subtypes and recombinants.	2003 May 2	12700461
Fusion inhibition--a major but costly step forward in the treatment of HIV-1.	2003 May 29	12773653
Novel therapies based on mechanisms of HIV-1 cell entry.	2003 May 29	12773651
Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia.	2003 May 29	12773645
HIV infection--a new drug and new costs.	2003 May 29	12773643
Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America.	2003 May 29	12637625
[HIV-1 fusion inhibitor improves treatment in HIV-1-resistant patients].	2003 May 9	12774800
New class of medications approved for advance HIV.	2003 May-Jun	12793380
Inhibiting HIV-1 entry with fusion inhibitors.	2003 Sep	12871113
Virus entry as a target for anti-HIV intervention.	2003 Sep	12871111

Sample Use Guides

In Vivo Use Guide

Adults: Recommended dosage of Enfuvirtide is 90 mg (1 mL) twice daily injected subcutaneously into the upper arm, anterior thigh, or abdomen. Pediatric Patients (weighing at least 11kg): Recommended dose of 2 mg/kg twice daily up to a maximum dose of 90 mg twice daily injected subcutaneously.

Route of Administration: Other

Substance Class	Protein Created by `admin` on `Thu Jul 06 21:51:20 UTC 2023` Edited by `admin` on `Thu Jul 06 21:51:20 UTC 2023`
Protein Sub Type
Sequence Type	COMPLETE
Record UNII	19OWO1T3ZE
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

ENFUVIRTIDE

Official Name

English

ENFUVIRTIDE [VANDF]

Common Name

English

DP-178

Code

English

T-20

Code

English

FUZEON

Brand Name

English

DP178

Code

English

enfuvirtide [INN]

Common Name

English

ENFUVIRTIDE [EMA EPAR]

Common Name

English

ENFUVIRTIDE [USAN]

Common Name

English

Enfuvirtide [WHO-DD]

Common Name

English

T20

Code

English

ENFUVIRTIDE [MART.]

Common Name

English

ENFUVIRTIDE [MI]

Common Name

English

ENFUVIRTIDE [ORANGE BOOK]

Common Name

English

ENFUVIRTIDE [HSDB]

Common Name

English

Classification Tree Code System Code

NDF-RT

N0000175616